This research develops nanobubble-enhanced ultrasound imaging as an accessible alternative to MRI for cancer diagnosis. Tiny gas-filled nanoparticles amplify ultrasound signals and improve image quality, particularly in prostate cancer. The technology could reduce diagnostic delays, lower costs, and provide high-quality medical imaging to more patients worldwide.

This research combines focused ultrasound and engineered genetic circuits to activate cancer immunotherapy directly within solid tumors. By locally triggering immune-stimulating cytokines such as IL-12, the approach aims to convert “cold” tumors into “hot” tumors while minimizing systemic toxicity, potentially expanding curative immunotherapy treatments to more cancer patients.

This research develops engineered ultrasonic reporters that allow ultrasound imaging to detect molecular activity rather than only anatomical structure. By targeting biological signals associated with cancer progression and cellular communication, the work aims to distinguish aggressive disease earlier and improve precision medicine through real-time, noninvasive monitoring of underlying cellular behavior.

This research develops “nanozymes,” nanoparticle-based catalysts that activate cancer drugs directly at tumor sites. Instead of carrying large amounts of chemotherapy drugs, nanozymes locally trigger inactive drugs into their active form only within cancer tissue. Early mouse studies show effective tumor destruction with significantly reduced side effects compared to conventional chemotherapy.

This research uses artificial intelligence to predict the progression of Alzheimer’s disease and cancer using medical imaging data. By analyzing brain scans, tumor scans, and treatment responses, AI models can forecast disease development and treatment outcomes, enabling earlier intervention, more personalized care, and improved quality of life for aging populations.

This research investigates taste alterations experienced by cancer patients during chemotherapy and radiotherapy. Using electrogustometry and flavour profile analysis, the study measures and categorizes changes in taste perception to guide the development of tailored food products that improve nutrition, comfort, and quality of life for people undergoing cancer treatment.

This research develops nanoscale “smart package” delivery systems for PROTAC cancer drugs. Antibody nanogel conjugates selectively target cancer cells, enter them, and release therapeutic molecules while minimizing exposure to healthy tissue. The approach improves delivery efficiency and aims to reduce the severe side effects that often limit cancer treatment.

This research develops synthetic genetic circuits that automatically alternate CAR T-cell activity between active cancer killing and recovery states. By preventing immune-cell exhaustion, these circuits could improve cancer immunotherapy effectiveness. The work also suggests broader biomedical applications where controlled cycling of gene activity may enhance treatment safety, longevity, and therapeutic performance.

This research uses spatial transcriptomics to map interactions between T cells, cancer cells, and immunosuppressive cells in tumours. Findings suggest cancer suppresses immune responses by surrounding and weakening T cells. The work aims to improve immunotherapy and enable personalised cancer treatment through detailed tumour mapping.

This research develops targeted radiopharmaceutical therapies for HER2-positive cancers. By attaching radioactive isotopes to trastuzumab, treatment delivers precise radiation to cancer cells, overcoming drug resistance. The work includes creating practical drug kits and aims to improve cancer outcomes by replacing non-specific therapies with highly accurate, targeted interventions.